Open AccessTralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
Author(s) -
Andrew Blauvelt,
Melinda Gooderham,
Neal Bhatia,
Richard Langley,
Shan Schneider,
John Zoidis,
Azra Kurbasic,
April W. Armstrong,
Jonathan I. Silverberg
Publication year - 2022
Publication title -
dermatology and therapy
Language(s) - English
Resource type - Journals
eISSN - 2193-8210
pISSN - 2190-9172
DOI - 10.1007/s13555-022-00805-y
Subject(s) - atopic dermatitis , medicine , dermatology , phase (matter) , pediatrics , organic chemistry , chemistry
In pivotal phase 3 tralokinumab monotherapy (ECZTRA 1/2) and topical corticosteroid (TCS) combination (ECZTRA 3) trials in adults with moderate-to-severe atopic dermatitis (AD), tralokinumab significantly improved signs and symptoms of AD. Geographic region may impact treatment response due to potential differences in race and ethnicity, and based on findings in other therapy areas. Here, we evaluated the efficacy and safety of tralokinumab in the ECZTRA 1/2/3 North American population at week 16, as well as maintenance of responses over time, and compared these data side-by-side with those of the ECZTRA 1/2/3 non-North American population.